Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582453 | 0.89 | TMEM97 (0.46) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL894510 | 0.80 | MEN1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3934434 | 0.79 | MEN1 (0.59) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL9727540 | 0.78 | NPSR1 (0.68) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL6132364 | 0.77 | GAA (0.69) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL27755151 | 0.77 | LMNA (0.43) | SIGMAR1HTR1AHTR2BLMNAADRB1 | |
| SCHEMBL975238 | 0.75 | NPSR1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL19950156 | 0.75 | MEN1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL12814257 | 0.75 | MEN1 (0.60) | MEN1KMT2ANPSR1TMEM97SIGMAR1 | |
| SCHEMBL19211095 | 0.74 | MEN1 (0.56) | MEN1KMT2ANPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | MEN1 4411/4885KMT2A 1321/4885NPSR1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.